Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study (Q33345785)

26 July 2017

Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study (English)

1 reference

26 July 2017

0 references

1 reference

Sanjiv S Agarwala

1

1 reference

PubMed ID

12491513

26 July 2017

John M Kirkwood

series ordinal

2

1 reference

PubMed ID

12491513

26 July 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

26 July 2017

1 reference

26 July 2017

97

1 reference

26 July 2017

1

1 reference

26 July 2017

121-127

1 reference

A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma

26 July 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11041

7 January 2021

DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11041

7 January 2021

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11041

7 January 2021

Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11041

7 January 2021

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11041

7 January 2021

Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11041

7 January 2021

Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11041

7 January 2021

Sequential chemoimmunotherapy in the treatment of metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11041

7 January 2021

Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11041

7 January 2021

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11041

7 January 2021

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11041

7 January 2021

Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11041

7 January 2021

O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11041

7 January 2021

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11041

7 January 2021

Population pharmacokinetics of temozolomide in cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11041

7 January 2021

Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11041

7 January 2021

Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11041

7 January 2021

Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11041

7 January 2021

Metastatic pattern of malignant melanoma. A study of 216 autopsy cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11041

7 January 2021

Identifiers

DOI

10.1002/CNCR.11041

1 reference

26 July 2017

1 reference

PubMed ID

12491513